Background; Rhizoxin (NSC 332598) is a novel macrolide antitumor antibiotic that inhibits microtubule assembly and also depolymerizes preformed microtubules. In preclinical evaluations, rhizoxin demonstrated broad antitumor activity in vitro and in vivo including both vincristine-and vindesineresistant human lung cancers. Prolonged exposure schedules in xenograft models demonstrated optimal efficacy indicating schedule-dependent antitumor activity. The early phase I and II evaluations a five-minute bolus infusion schedule was studied, however, only modest anti-tumor activity was noted, possibly due to rapid systemic clearance. To overcome these limitations and to exploit the potential for scheduledependent behavior of rhizoxin, the feasibility of administering rhizoxin as a 72-hour continuous intravenous (i.v.) infusion was evaluated.
Introduction
Rhizoxin (NSC 332598), a macrolide antitumor antibiotic derived from the plant fungus Rhizopsis chenensis, exerts its cytotoxic effect through high affinity binding to the vinca alkaloid binding site of tubulin, inhibition of the tubulin-dependent guanosine triphosphate hydrolysis necessary for tubulin polymerization and microtubule assembly [1, 2] . Rhizoxin can also extensively depolymerize preformed microtubules [2] . Furthermore, rhizoxin inhibits microtubule assembly at a 10-fold lower concentration (10 ng/ml) than vincristine and is 8-to 43-fold more active than vincristine in P-glycoprotein-mediated vincristine-resistant murine and human leukemia cell lines (P388/VCR and K562/VCR) [3] . These unique attributes of rhizoxin, as well as high potency and non-cross resistance with vinca alkaloids led to the clinical development of this novel antimicrotubule agent.
Rhizoxin demonstrated broad cytotoxic activity in vitro in the National Cancer Institute (NCI) tumor cell line screening panel [4] . In comparison to the standard agent database generated by the NCI's COMPARE program, rhizoxin's antitumor activity strongly correlated with other antimitotic agents including maytansine, vincristine, vinblastine, and paclitaxel (r = 0.7480-0.911) [4] . In contrast to other antimicrotubule agents, rhizoxin demonstrated potent cytotoxicity over an exceptionally broad range of concentrations (10~4 to 10~1 3 M) [4] . Rhizoxin also demonstrated significant antitumor activity in a number of human tumor xenografts including melanoma (LOX), breast cancer (MX-1), nonsmall-cell lung cancer (A549), small-cell lung cancer (LXFS 605), and a vincristine-resistant small-cell lung cancer (LXF 650) [4] . Furthermore, rhizoxin was active in a non-P-glycoprotein-mediated vindesine-resistant human small-cell lung cancer cell line (H69/VDS) indicating that rhizoxin can overcome resistance mediated by altered vindesine binding of tubulin [5] . Clinical development of this agent was initiated based on the broad antitumor activity of rhizoxin and the absence of complete cross resistance with other known vinca alkaloid antimicrotubule agents.
The early clinical development of rhizoxin was performed by the European Organization for Research and Treatment of Cancer (EORTC) using a five-minute i.v. infusion repeated at three-week intervals [6] . Leukopenia, mucositis, and diarrhea were the predominant dose-limiting toxicities, with the maximum tolerated dose (MTD) determined to be 2.6 mg/m 2 [6] . In both the initial phase I and subsequent phase II studies, rhizoxin's pharmacokinetic profile was characterized by rapid clearance with a short elimination half-life of approximately 10 minutes [6, 7] . Plasma concentrations of rhizoxin were undetectable at dose levels below 2.0 mg/m 2 and at blood sampling beyond 30 minutes from drug administration. In phase II studies using this schedule, modest objective activity was observed in non-small-cell lung and squamous-cell carcinoma of the head and neck with response rates of 15% and 8%, respectively [8, 9] .
The antitumor activity of rhizoxin appears to be schedule-dependent. In human tumor xenograft studies, repeated daily drug dosing schedules resulted in superior antitumor activity compared to single dosing or less frequent repeated dosing schedules [4] . Therefore, to fully explore the schedule-dependent nature of rhizoxin, prolonged infusion schedules would need to be initiated.
The decision to pursue a more protracted 72-hour continuous intravenous (i.v.) administration schedule was based on the potent and unique preclinical activity of rhizoxin, evidence of superior antitumor efficacy with prolonged exposure schedules in preclinical models, and to overcome the brief plasma half-life of rhizoxin observed with bolus injection. The principal objectives of this study were to: (1) determine the maximum tolerated dose (MTD) of NSC 332598 when administered as a 72-hour continuous i.v infusion every three weeks; (2) evaluate the qualitative and quantitative toxicities of NSC 332598 when administered on this schedule; (3) characterize the pharmacokinetic behavior of NSC 332598; (4) preliminarily assess antitumor activity of NSC 332598 in patients with advanced malignancies.
Patients and methods

Patient selection
Patients with histologically or cytologically confirmed solid malignancies refractory to standard therapies or for whom no standard therapy existed were eligible. Patient entry criteria also included: (1) age > 18 years, (2) life-expectancy of at least 12 weeks, (3) Southwest Oncology Group (SWOG) performance status of 0-2, (4) no treatment with chemotherapy in the preceding 4 weeks (6 weeks for prior mitomycin C or nitrososureas), (5) measurable or evaluable disease, and (6) adequate hematopoeitic (hemoglobin > 9 g/dl, absolute neutrophil count (ANQ 5:1500/mm 3 , platelet count > 100,000/mm 3 , hepatic (bilirubin <1.5 mg/dl, aspartate serum transferase (AST) $ 3 times upper limit of normal), and renal (creatinine <1.5 mg/dl) functions. Patients were excluded if they had evidence of an active infection, congestive heart failure, unstable angina, or a myocardial infarction within six months of study entry.
Drug administration
The initial starting dose for NSC 332598 was 0.2 mg/m 2 administered as a 12-hour i.v. infusion once every three weeks. This starting dose represented 1 /6th of the MTD determined using the five-minute i.v. bolus schedule. Dose-escalation and schedule prolongation were performed in successive cohorts of one to three patients until a maximum infusion duration of 72-hours was reached, after which dose-escalation only was performed. Double dose escalation by one patient was permitted if no patient experienced grade > 2 toxicity. If one patient experienced dose-limiting toxicity (DLT) cohorts were expanded to six patients. Dose reductions by one dose level were permitted for DLT, which was defined as either an ANC less than 500/ul for at least five days and/or associated with fever that required hospitalization for parenteral antibiotic therapy; a platelet count less than 25,000/ul; grade 3 or higher non-hematologic toxicity (including grade > 3 nausea or vomiting despite antiemetics), and any unresolved toxicity that resulted in treatment delays of at least two weeks. Toxicities were graded according to the NCI's Common Toxicity Criteria. The MTD was defined as the dose in which no more than one of six patients had dose-limiting toxicity (DLT) during cycle 1.
Rhizoxin (NSC 332598) was supplied by the NCI (Bethesda, Maryland) in vials containing 5 mg of rhizoxin, with 25 mg mannitol, USP, and 25 mg of ascorbic acid, USP as a white lyophylized powder. Each vial of rhizoxin was reconstituted with 2.5 ml of sterile propylene glycol 80% and ethanol 20% (v/v). Prior to administration, 2.5 ml of sterile water was added and the solution was further diluted with 10% fat emulsion (1:100 up to 1:10; v/v).
Pretrearment and follow-up studies
A complete medical history, physical examination, concomitant medication profile, assessment of SWOG performance status, and routine laboratory studies were performed on day 1 of each course of treatment with NSC 332598. Routine laboratory studies included a complete blood count (CBC), differential white blood count (WBQ, prothrombin and partial thromboplastin time, electrolytes, blood urea nitrogen, serum creatinine, uric acid, glucose, alkaline phosphatase, lactate dehydrogenase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, calcium, total protein, albumin, cholesterol, and triglycerides. Urinalysis and serum pregnancy test (as appropriate) were performed at baseline. An interval history, toxicity assessment, physical examination, aforementioned routine lab studies were performed weekly.
Assessments of evaluable and measurable disease were performed within four weeks of the initiation of treatment and repeated every six weeks. A complete response was defined as the total disappearance of all measurable and evaluable disease for at least two measurements separated by a minimum of four weeks. A partial response was defined as a 50% or greater reduction in the sum of the products of the bidimensional measurements of all measurable lesions documented by two measurements separated by a minimum period of four weeks apart.
Pharmacokinetic sampling and assay
To study the pharmacokinetics of rhizoxin, whole blood samples were obtained from indwelling venous catheter placed in the arm contralateral to the drug infusion during the first course of treatment. Samples (0.6 mg/ml), and HEPES buffer (2 mM). Cells were plated in 35 mm Petri dishes in a top layer of agar and an underlayer of 0.3% agar to prevent growth of fibroblasts. Three plates were prepared for each data point. During the 1-hour exposure studies, the cells were incubated with the drug in McCoy's medium and then washed. The number of colonies (defined as greater than 50 cells) formed in the treated-plates were compared to the number of colonies in the untreated control plates and the percentage of surviving colonies at each concentration was calculated.
were obtained prior to the infusion and at 2, 6, and 12 hours for all patients. End of infusion sampling was performed for the 24-, 48-, and 72-hour intervals for patients treated on those infusion intervals. All specimens were immediately centrifuged and the plasma removed and then frozen at -20 °C.
The rhizoxin plasma levels on the 72-hour schedule of administration were predicted to be below the lower limit of sensitivity (1 ng/ml) of previous published high-performance liquid chromatography (HPLQ assays [7] . To increase the sensitivity of the HPLC assay, attempts were made to synthesize fluorescent derivatives that could be detected with a laser-induced fluorescent detector. Two methods to form rhizoxin derivatives were used. In the first method, rhizoxin was reacted with fluorescein acyl azide via a Curtius rearrangement. The second method 7-methoxy coumarin acyl azide was reacted with rhizoxin. The reaction was carried out in dichloromethane, tetrahydrofuran and acetonitrile.
Results
Nineteen patients received a total of thirty-two courses of rhizoxin at doses ranging from 0.2 mg/m 2 over twelve hours to 2.4 mg/m 2 over seventy-two hours every three weeks. The pertinent characteristics are summarized in Table 1 . The median number of courses administered per patient was 2 (range 1-3). All nineteen patients had received prior chemotherapy and the median number of prior chemotherapy regimens was 2 (range 1-6). The dose-escalation scheme, as well as the number of patients, courses administered, and number of DLTs as a function of dose level, is listed in Table 2 .
No objective antitumor responses were observed in this study.
Human tumor cloning assay
Tumor specimens were obtained using standard sterile techniques from patients undergoing diagnostic or therapeutic procedures. Specimens included solid tumors, malignant pleural effusions, ascites, and bone marrow aspirates. All patients gave written informed consent in accordance with federal and institutional guidelines. The processing and full assay methodology has been described previously [10, 11] .
Rhizoxin was supplied by the Division of Cancer Treatment, NCI. Stock solutions of rhizoxin were prepared in sterile, enriched Connaught Medical Research Laboratory Medium 1066 (Irvine Scientific, Irvine, California). One-half milliliter aliquots of each stock solution were labeled and stored at -70 °C. Aliquots were thawed for each new tumor sample tested. The final concentrations of rhizoxin tested were 0.02 and 0.2 ng/ml as a one-hour exposure.
Tumor cells were suspended in 0.35% agar in enriched CMRL 1066 Medium (Irvine Scientific, Irvine, California) supplemented with 15% heat-inactivated horse serum, penicillin (100 units/ml), streptomycin (2 mg/ml), glutamine (2 mM), insulin (3 units/ml), asparagine
Toxicities
Neutropenia was the principal severe toxic effect observed in this study. At the 2.4 mg/m 2 /72-hour dose level, a single minimally pretreated patient developed a constellation of toxicities, including grade 4 neutropenia with fever, grade 4 mucositis, and grade 1 diarrhea. The patient expired due to these toxic effects. Further patient accrual resumed at the 1.2 mg/m 2 /72-hour dose level with only one of seven patients entered experiencing DLT (grade 4 neutropenic and fever). This same minimally pretreated patient also experienced neutropenia (grade 2) with fever during the second course despite a 50% reduction of rhizoxin to 0.6 mg/m 2 /72 hours. Thereafter, additional patients were entered at an intermediate dose level of 1.6 mg/m 2 /72 hours, which was (1) 1 (1) 4 (5) 1 (1) 2(2) 1(1)
1(1)
Number of patients experiencing toxicity during course 1 (all courses). * Includes patients subsequently dose reduced on their second cycle.
associated with DLT during the first course in three of seven patients. These dose-limiting events consisted of grade 4 neutropenia lasting longer than five days without fever in two patients, and grade 4 neutropenia with fever, grade 4 thrombocytopenia and grade 4 mucositis in one patient. In addition, the patient with the most severe toxicity at this dose-level (grade 4 neutropenia, grade 4 thrombocytopenia, grade 4 mucositis) also experienced painful erythema of the soles of the feet, and concurrent hyperbilirubinemia which were possibly due to progressive growth of liver metastases. The patient who subsequently expired on day 21 due to progressive cancer was the only subject who experienced significant thrombocytopenia (grade ^ 3) in this study. At the MTD of 1.2 mg/m 2 /72 hours hematologic toxicit was modest. The median ANC nadir at this level was 2359/ul (range 31-3640/mm 3 ), and the median platelet nadir was 136,000/ul (range 83-351,000/uT). Hematologic toxicity as a function of dose-level is summarized in Table 3. A total of four patients experienced severe (grade Js 3) neutropenia associated with fever at the following dose levels: 1.2 mg/m 2 (one patient), 1.6 mg/m 2 (two patients), and 2.4 mg/m 2 (one patient). No significant toxicity was observed in the first four dose levels, nor in the initial patient treated at the 1.2 mg/m 2 /72-hour dose, which resulted in a doubling of the dose to 2.4 mg/m 2 /72 hours.
Non-hematologic toxicity was common but generally mild. Two patients experienced dose-limiting grade 4 mucositis, as previously described, at the 1.6 and 2.4 mg/m 2 dose level. Less severe mucositis was observed in four patients (grade 1 [three patients at 1.6 mg/m 2 ] and grade 2 [one patient at 1.2 mg/m 2 ]). Mild diarrhea (grade 1) occurred in six patients (four patients at 1.6 mg/m 2 and one each at 1.2 and 2.4 mg/m 2 ) while one patient experienced an upper gastrointestinal hemorrhage with melena that was likely due to their underlying duodenal leiomyosarcoma. Other possible or probable toxic effects that were mild in severity included malaise, anorexia, anemia, hoarseness, alopecia, hepatic transaminase elevations, nausea and vomiting. The significant non-hematologic toxicities are summarized in Table 4 . 
Pharmacokinetic assay
The plasma rhizoxin concentrations were below the lower level of detection for the previously reported HPLC method (1 ng/ml). Rhizoxin has a low level of intrinsic fluorescence. To increase the sensitivity of the HPLC assay, two methods to generate fluorescent rhizoxin derivatives were attempted. Initially rhizoxin was reacted with fluorescein acyl azide but formation of a fluorescent rhizoxin product failed. Since both rhizoxin and fluorescein are bulky molecules, steric hinderance was felt to be responsible for the lack of product. To overcome this a smaller agent, 7-methoxy coumarin, was employed. Based on a report describing the derivation of cholesterol for fluorescent labeling and ultrasensitive detection by HPLC assay, 7-methoxy coumarin acyl azide was reacted with rhizoxin [12] . The reaction was carried out in dichloromethane, tetrahydrofuran and acetonitrile. Again, fluorescent rhizoxin derivatives were not generated. Further attempts to generate rhizoxin derivatives were not performed.
Human tumor cloning assay
Concurrent with the conduct of the clinical evaluation, 52 fresh human tumors were treated with rhizoxin for 1 hour in a human tumor cloning assay summarized in Table 5 . Preliminary antitumor responses (<50% colony survival compared to controls) were observed at the lowest concentration (0.02 ug/ml) of rhizoxin in stomach (2 of 2 tumors), head and neck (1 of 1), neuroblastoma 
Discussion
Rhizoxin is a unique antimicrotubule agent that demonstrates potent antitumor activity in a broad spectrum of human tumor cell lines including those resistant to vinca alkaloids. In this phase I study of rhizoxin, the infusion schedule of rhizoxin was prolonged to overcome the rapid plasma clearance observed with the 5-minute infusion schedule and to explore the schedule-dependent improvement in antitumor activity observed preclinically. The MTD of rhizoxin when administered over 72 hours was determined to be 1.2 mg/m 2 . The predominant toxicity that limited further dose-escalation was neutropenia. Other dose-related toxicities included mucositis, thrombocytopenia and diarrhea. Since mucositis was also a prominent toxicity at the higher dose levels, the use of granulocyte colony-stimulating factors to permit further dose-escalation was not projected to be a viable strategy.
A rapid dose escalation scheme was used to minimize the number of patients who were treated at doses below the MTD. However, unacceptable and severe toxicities occurred at both the 1.6 and 2.4 mg/m 2 dose levels that was not anticipated by the absence of toxicity observed in the first patient treated at 1.2 mg/m 2 /72 hours. This finding should illustrate the potential for a marked escalation in toxicity between dose levels that cannot be predicted, with confidence, using single patient cohorts.
Despite the different schedule of rhizoxin administration used in this study, the toxicity profile was very similar to that reported in the EROTC study using a five-minute i.v. schedule [6] . In both studies, neutropenia, mucositis and diarrhea were the predominant clinical toxicities preventing further dose escalation [6] . In the EROTC study grade 4 neutropenia, life-threatening sepsis, grade 3 mucositis and grade 3 diarrhea occurred at 2.6 mg/m 2 . These same toxicities were observed at the 2.4 mg/m 2 and 1.6 mg/m 2 dose levels with the 72-hour i.v. infusion. At the MTD for both the 5-minute and 72-hour infusion schedules neutropenia, diarrhea, and mucositis were still observed but both less common and severe.
One notable difference in the toxicity profiles between the 5-minute and 72-hour infusion schedule was the absence of peripheral neuropathy with the prolonged infusion schedule. Mild to moderate peripheral sensory neuropathy was observed in 25% of patients treated at doses above 1.6 mg/m 2 with the 5-minute infusion study, but was not observed in any patient treated with rhizoxin as a 72-hour infusion in the present study [6] . The schedule-dependent nature of peripheral neurotoxicity has also been observed with other antimicrotubule agents. For example, a decreased incidence of symptomatic sensory neuropathy has been previously observed with prolonged infusion schedules of vinorelbine and paclitaxel [13, 14] . In a randomized study comparing the toxicity and effectiveness of paclitaxel administered by either a 3-or 96-hour infusion, Holmes et al. reported significantly less paclitaxel-induced neuropathy in the 96-hour arm despite similar cumulative doses [15] . The presence of peripheral neuropathic symptoms with the five-minute schedule and absence in the current study suggest that rhizoxin neurotoxicity is associated with high rhizoxin plasma concentrations, and the incidence and severity of this toxicity may be reduced by increasing the duration of infusion.
Despite attempts develop a sensitive analytical assay to measure rhizoxin, the drug was not detected in the plasma of patients receiving the 72-hour infusion. Previous investigators have also had difficulty detecting rhizoxin at low doses when administered over five minutes [6, 7] . In the EROTC phase I study, a HPLC method with a lower limit of detection to 5 ng/ml could detect plasma rhizoxin concentrations only at doses of 2.0 mg/m 2 administered over five minutes [6] . Using a similar methodology but with a lower limit of quantification (1 ng/ml), McLeod et al. examined blood samples collected from patients entered into four separate phase II studies of rhizoxin [7] . In these studies, 68 patients underwent blood sampling and 53 patients had detectable rhizoxin concentrations. The remaining patients were not evaluable because of an interfering peak in pretreatment samples (10 patients), or no detectable plasma rhizoxin concentrations (5 patients). Only 37 patients had rhizoxin detectable on more than one sample. At 20 minutes post-infusion, only 25% of patients had detectable rhizoxin in the plasma [7] . It is not surprising therefore, that the HPLC method was not sufficiently sensitive to detect plasma rhizoxin concentrations in any patient treated with the current 72-hour i.v. infusion schedule. Although attempts were made to develop a more sensitive rhizoxin HPLC assay by labeling rhizoxin with either fluorescein or 7-methoxy coumarin, they were nonetheless unsuccessful. A preliminary report suggests liquid chromatography/mass spectrophotometry method may detect plasma rhizoxin in patients receiving a 72-hour infusion [16] .
Since antitumor responses were not observed with this prolonged infusion schedule, pharmacokinetic data would have been helpful in determining whether biologically relevant drug concentrations were being achieved. The preliminary response data from the human tumor cloning assay (1-hour exposure) suggested some anti-cancer activity at concentrations of 0.02 ug/ml and 0.2 ng/ml; which substantially exceed the expected range achieved with the 72-hour continuous i.v. schedule. However, since rhizoxin demonstrated potent antitumor activity in vitro at concentrations as low as 10~1 3 M, the low plasma rhizoxin concentrations attained with the 72-hour infusion may nevertheless be still within a therapeutic range [4] . Confirming whether therapeutic concentrations are achieved with a prolonged infusion schedule awaits the development of a sufficiently sensitive rhizoxin assay and subsequent phannacologic directed studies of this schedule. However, the limitations encountered with this schedule include a toxicity profile similar to the bolus administration schedule, undetectable rhizoxin concentrations by currently available assays, and the added complexity of prolonged ambulatory intravenous infusion schedule. These limitations suggest other schedules of rhizoxin administration should be explored. The preliminary results for other antimicrotubule agents (e.g., docetaxel, paclitaxel, and vinorelbine) administered on weekly schedules appear to maintain antitumor effectiveness while reducing toxicity [17] [18] [19] . Administering rhizoxin on a weekly administration schedule may represent an alternate strategy worth exploring.
